The T1D Fund aims to accelerate the delivery of treatments, preventions, and cures for T1D patients by partnering with private capital, including venture capital, pharma, and foundations. The fund will prioritize the best commercial opportunities in artificial pancreas systems, metabolic control, beta cell replacement, prevention, and beta cell restoration therapies. Founded in 2016, the Boston-based firm plans to reinvest any realized gains into new investments to further its mission. The JDRF T1D Fund is a mission-driven venture philanthropy platform focused on investment in early-stage T1D commercial opportunities.